1. MMV-supported projects
Research
Translational
Product development
Access
Lead optimization
Candidate profiling
Human volunteers
Patient exploratory
Patient confirmatory
Regulatory review
Approved/ ERP
Preclinical
Miniportfolio
GSK
Pantothenates
TropIQ/RUMC
MMV253
Zydus Cadila
P218
Janssen
SJ733
Kentucky/Eisai
DSM265
Takeda
MMV048
Cipargamin
Novartis
Artefenomel/
Ferroquine
Sanofi
Ganaplacide /
Lumefantrine
Dihydroartemisinin- piperaquine dispersible
Alfasigma
Sulfadoxine-
pyrimethamine+
amodiaquine dispersible S Kant
Artemether-
lumefantrine
Dispersible
Novartis 3 1
Phenotypic Lead
Daiichi-Sankyo
SAR121
Sanofi
Tafenoquine paediatric GSK
Artesunate
for Injection
Fosun (Guilin) 2
Open Source Series
University of Sydney
MMV370
MMV371
M5717
Merck KGaA
Dihydroartemisinin- piperaquine
Alfasigma 3
Phe tRNA ligase
Broad Institute/Eisai
MMV052
Pyronaridine-
artesunate
Shin Poong 4
Purines
Celgene
Pyronaridine- artesunate granules
Shin Poong 4
GWT1
Eisai
Artesunate-
amodiaquine
Sanofi 5
Molecular Target
DDU Dundee
Artesunate-
mefloquine
Cipla
Azabenzimidazole
UNICAMP
MMV support to projects may include financial, in-kind, and advisory activities.
Footnotes: Included in MMV portfolio after product approval and/or development. DNDi and partners completed development and registration of ASMQ and ASAQ. │ Global Fund Expert Review Panel (ERP) reviewed product – permitted for time-limited procurement, while regulatory/WHO prequalification review is ongoing. │ WHO Prequalified OR approved/positive opinion by regulatory bodies who are ICH members/observers. │ Paediatric formulation.
Sulfadoxine-
pyrimethamine+
amodiaquine
Fosun (Guilin) 6
Miniportfolio
Novartis
DHODH
UTSW/ UW/ Monash
Rectal artesunate
Cipla 7
SJ733 backup
Kentucky
Phenotypic Lead
UCT
Rectal artesunate
Strides Pharma
Brand names 1: Coartem® Dispersible; 2: Artesun®; 3: Eurartesim®; 4: Pyramax® tablets or granules; 5: ASAQ Winthrop®; 6: SPAQ-COTM ; 7: 100mg Artesunate Rectocaps; 8: ArtecapTM ; 9: Kozenis/Krintafel (Trademarks owned or licensed by GSK) 8
Phenotypic Lead
Sanofi
Intra-muscular
Calibr
Artesunate
for Injection
Ipca
Tafenoquine
GSK 9

2. Footnotes: MMV-supported projects
Target Product Profiles and Target Candidate Profiles
MMV has defined Target Product Profiles and Target Candidate Profiles for medicines to support the eradication campaign.
Burrows JN et al., New developments in anti‑malarial target candidate and product profiles et al. Malar J (2017) 16:26 updates the previous profiles in Burrows J et al.; Malaria Journal :187
Target Product Profiles
indicated by bars at the bottom of each compound box
Target Candidate Profiles
activities for each individual molecule, indicated by symbols added to each compound in the translational portfolio
Burrows Burrows
et al., 2013 et al., 2017
Asexual blood stages (TCP-1,2) TCP-1
Relapse prevention (TCP-3a) TCP-3
Transmission reduction (TCP-3b) TCP-5,6
Chemoprotection (TCP- 4) TCP-4
3-day cure, artemisinin-based combination therapies
Uncomplicated malaria treatments aiming at a new single-exposure radical cure (SERC) TPP-1
Severe malaria treatment / pre-referral intervention
Intermittent /seasonal malaria chemoprevention
Products targeting prevention of relapse for P. vivax
Single-exposure chemoprotection (SEC) TPP-2